<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05099198</url>
  </required_header>
  <id_info>
    <org_study_id>DUPLICATE-GRADE</org_study_id>
    <nct_id>NCT05099198</nct_id>
  </id_info>
  <brief_title>Replication of the GRADE Diabetes Trial in Healthcare Claims Data</brief_title>
  <official_title>Replication of the GRADE Diabetes Trial in Healthcare Claims Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators are building an empirical evidence base for real world data through large-scale&#xD;
      replication of randomized controlled trials. The investigators' goal is to understand for&#xD;
      what types of clinical questions real world data analyses can be conducted with confidence&#xD;
      and how to implement such studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized, non-interventional study that is part of the RCT DUPLICATE&#xD;
      initiative (www.rctduplicate.org) of the Brigham and Women's Hospital, Harvard Medical&#xD;
      School. It is intended to replicate, as closely as is possible in healthcare insurance claims&#xD;
      data, the trial listed below/above. Although many features of the trial cannot be directly&#xD;
      replicated in healthcare claims, key design features, including outcomes, exposures, and&#xD;
      inclusion/exclusion criteria, were selected to proxy those features from the trial.&#xD;
      Randomization is also not replicable in healthcare claims data but was proxied through a&#xD;
      statistical balancing of measured covariates according to standard practice. Investigators&#xD;
      assume that the RCT provides the reference standard treatment effect estimate and that&#xD;
      failure to replicate RCT findings is indicative of the inadequacy of the healthcare claims&#xD;
      data for replication for a range of possible reasons and does not provide information on the&#xD;
      validity of the original RCT finding.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Actual">August 1, 2021</completion_date>
  <primary_completion_date type="Actual">August 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time until failure to maintain metabolic control</measure>
    <time_frame>Through censoring or study completion, up to 765 days after cohort entry</time_frame>
    <description>Lab based algorithm: time until failure to maintain metabolic control (HbA1c level &gt;= 7.0% or 53 mmol/mol)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time until a severe hypoglycemic episode</measure>
    <time_frame>Through censoring or study completion, up to 765 day after cohort entry</time_frame>
    <description>Claims based algorithm: time until a severe hypoglycemic episode</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1C change from baseline</measure>
    <time_frame>Through censoring or study completion, up to 765 days after cohort entry</time_frame>
    <description>Lab based algorithm: HbA1C change from baseline</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">6403</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <description>Reference group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepiride</arm_group_label>
    <description>Exposure group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin dispensing claim is used as the reference</description>
    <arm_group_label>Sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>Glimepiride dispensing claim is used as the reference</description>
    <arm_group_label>Glimepiride</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with type 2 diabetes who have previously been treated with metformin.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age greater or equal than 30: days [0,0]&#xD;
&#xD;
          -  Diagnosis of Type 2 Diabetes: days [- All Data, 0]&#xD;
&#xD;
          -  2+ recorded HbA1c levels: days [-365,0]&#xD;
&#xD;
          -  Metformin use: days [-30, 0]&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 or Secondary DM: days [-All Data, 0]&#xD;
&#xD;
          -  Previous organ transplant: days [-All Data, 0]&#xD;
&#xD;
          -  HIV/AIDS: days [-All Data, 0]&#xD;
&#xD;
          -  History of bariatric surgery: days [-All Data, 0]&#xD;
&#xD;
          -  Congestive heart failure: days [-All Data, 0]&#xD;
&#xD;
          -  NYHA &gt;=3: days [-All Data, 0]&#xD;
&#xD;
          -  Pancreatitis: days [-All Data, 0]&#xD;
&#xD;
          -  Medullary thyroid cancer/MEN-2: days [-All Data, 0]&#xD;
&#xD;
          -  History of MI: days [-365, 0]&#xD;
&#xD;
          -  Stroke: days [-365, 0]&#xD;
&#xD;
          -  Coronary Revascularization: days [-365, 0]&#xD;
&#xD;
          -  PTCA/Stenting/CABG: days [-365, 0]&#xD;
&#xD;
          -  Trans myocardial revascularization: days [-365, 0]&#xD;
&#xD;
          -  Carotid bypass: days [-365, 0]&#xD;
&#xD;
          -  Cerebrovascular revascularization: days [-365, 0]&#xD;
&#xD;
          -  PVD: days [-365, 0]&#xD;
&#xD;
          -  CCI &gt;=10: days [-365, 0]&#xD;
&#xD;
          -  History of cancer, other than non-melanoma skin cancer: days [-1,825, 0]&#xD;
&#xD;
          -  Treatment of metformin more than 10 years: days [-3,650, 0]&#xD;
&#xD;
          -  Treatment with any diabetes drug other than metformin; PCOS; symptomatic&#xD;
             hyperglycemia; pregnancy; gestational diabetes: days [-180, 0]&#xD;
&#xD;
          -  History of hemolytic anemia; history of severe liver disease; current alcoholism;&#xD;
             chronic transfusion requirement; ESRD: days [-180, 0]&#xD;
&#xD;
          -  Oral, IV, or IM cortisone, hydrocortisone, prednisone, methylprednisone, or&#xD;
             dexamethasone: days [-90, 0]&#xD;
&#xD;
          -  Treatment with atypical antipsychotics, language barriers, nursing home, or missing&#xD;
             age or gender: days {-180, 0]&#xD;
&#xD;
          -  Hospitalization with length of stay &gt;3 days: days [-30, 0]&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shirley Wang, PhD, ScM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jessica Franklin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 25, 2021</study_first_submitted>
  <study_first_submitted_qc>October 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Jessica Franklin</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 13, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT05099198/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

